A variety of bacteria, such as those responsible for Lyme disease, dental infections, and medical implanted device infections present a very interesting and medically important feature. They have the ability to create biofilms. This biofilm is formed by the bacteria when they attach to both living and non-living surfaces. The human digestive tract and blood stream are places where biofilms thrive, but they can also be visualized in a brain tissue sample of infected persons. Because of these biofilms, antibiotics can not fully eradicate the infectious organisms. In addition, Borellia, the bacteria that causes Lyme disease, also has the ability to modify its surface proteins making it unrecognizable by the immune system, which typically fights infections. Specifically, it affects the Th1 helper T cells and natural killer T cell which are key components of the immune system. Treatment with Boluoke for lyme disease and other infections enables the immune system to recognize the bacteria and fight against the infection.
It is estimated that over 99% of all bacteria live in biofilm communities and the National Institutes of Health indicates that 60% of all human infections and 80% of infections unresponsive to medical treatment are attributable to biofilm colonies. As a result, many doctors and researchers and clinicians suggest that the eradication of many infections may be possible by targeting these biofilms.
Boluoke (also known as Lumbrokinase), a purified mix of enzymes from Lumbricus rubellus (earthworm), make be a great therapeutic treatment for bacterial infections, because it helps break down the biofilms. Boluoke contains six enzymes derived from the digestive tract of the 2 species of earthworm Red Wriggler or Red Marsh, which are usually found in apple orchards. Therapy with earthworms is not new at all. It has been used by practitioners of Chinese Medicine since ancient times. In China, it is primarily used to prevent and treat blood clots and the administration of this supplement to over 60,000 Chinese patients has revealed no adverse side effects.
Boluoke contains two key substances involved in blot clotting: plasminogen activator and plasmin. Normally these substances are produced when the body forms fibrin as the result of injury. The connection between Lyme and other biofilm producing bacteria infections is the following: these bacteria are hiding from the immune system by creating a state of hyper (or excessive) coagulation. As a result, a substance called fibrin is activated and lays down a cover over the bacteria and therefore the immune system does not recognize them and therefore does not fight these infections.
In summary, Boluoke appears to assist in dissolving the excess fibrin that covers and hides the bacteria, is involved in the regulation of blood clotting and also eliminates the abnormal proteins that are released as a result of the bacteria’s activity.
Boluoke is available in supplement form, in capsules containing Lumbrokinase 600,000 IU (or 40 mg). The suggested daily dose is one or two capsules in the morning, afternoon and bedtime, although a healthcare professional should be consulted (especially if it is used in addition to anticoagulant drugs). It is also suggested to be taken with water, with or without food. Boluoke is contraindicated in all medical conditions associated with an increased risk of bleeding.